Adalimumab

Indication

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Red

Brand:

Humira®

Nice TA:

383

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Musculoskeletal system

Background

Adalimumab is recommended, within its marketing authorisations, as an option for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Axial Spondyloarthritis Pathway Version 1.3

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - Mar - 2016

Breadcrumb